

Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress™ Meeting

PALO ALTO, Calif., March 5, 2018 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that abstracts from its LOWR HDV (Lonafarnib With Ritonavir in Hepatitis Delta Virus) Program will be presented at The International Liver Congress™ meeting in Paris, France, April 11 to 15, 2018.

Accepted abstracts to The International Liver Congress™ are listed below:

- *Yurdaydin, C. et al; “Subanalysis of the LOWR HDV-2 study reveals high response rates to lonafarnib in patients with low viral loads”; Parallel session: HBV and HDV: Current and emerging treatments, Abstract # PS-161, Oral Presentation, April 14, 9:15 am – 9:30 am CET, South 4.*
- *Dahari, H. et al; “Pharmacokinetics and pharmacodynamics modeling of ritonavir boosted lonafarnib therapy in HDV patients: A phase 2 LOWR HDV-3 study”; Viral Hepatitis B/D: Therapy, Abstract # FRI-323, Poster Presentation, April 13, 9:00 am – 5:00 pm CET, Poster Area.*

Other HDV events during The International Liver Congress™:

- *15th Hepatitis Delta International Network (HDIN) Meeting
April 11, 5:30 pm - 8:00 pm CET.*

*Apelian et al; “Update on Eiger Registrational Program for Chronic HDV”;
Oral Presentation, Room West 3.*

About Lonafarnib

Lonafarnib is a well-characterized, late-stage, orally active inhibitor of farnesyl transferase, an enzyme involved in modification of proteins through a process called prenylation. HDV uses this host cell process inside liver cells to complete a key step in its life cycle. Lonafarnib inhibits the prenylation step of HDV replication inside liver cells and blocks the virus life cycle at the stage of assembly. Lonafarnib has been dosed in over 120 HDV-infected patients across international academic centers and has completed Phase 2 development for HDV. Our lead program in Hepatitis Delta Virus (HDV) infection, is moving into Phase 3 with a single, pivotal trial planned to initiate by the end of the year. Lonafarnib has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and European Medicines

Agency (EMA), and Fast Track Designation by U.S. FDA. Lonafarnib is not approved for any indication, and is licensed from Merck Sharp & Dohme Corp. (known as MSD outside of the United States and Canada).

About Hepatitis Delta Virus (HDV)

Hepatitis Delta is caused by infection with HDV and is considered to be one of the most severe forms of viral hepatitis in humans. Hepatitis delta occurs only as a co-infection in individuals harboring Hepatitis B Virus (HBV). Hepatitis delta leads to more severe liver disease than HBV alone and is associated with accelerated liver fibrosis, liver cancer, and liver failure. Hepatitis delta is a disease with a significant impact on global health, which may affect up to approximately 15-20 million people worldwide. The prevalence of HDV varies among different parts of the world. Globally, HDV infection is reported to be present in approximately 4.3% to 5.7% of chronic Hepatitis B carriers. The prevalence of HDV in patients infected with chronic HBV is even higher in certain regions, including certain parts of Mongolia, China, Russia, Central Asia, Pakistan, Turkey, Africa, Middle East and South America, with an HDV prevalence as high as 60% being reported in HBV-infected patients in Mongolia and Pakistan.

About Eiger

Eiger is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases. We are committed to translational innovation and the development of well-characterized drugs acting on newly identified or novel targets. Our mission is to systematically reduce the time and cost of the drug development process to more rapidly deliver important medicines to patients with rare diseases. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Note Regarding Forward-Looking Statements

This press release contains “forward-looking” statements that involve substantial risks and uncertainties. All statements other than statements of historical facts, including statements regarding our future financial condition, timing for and outcomes of clinical results, business strategy and plans and objectives for future operations, are forward looking statements. These forward-looking statements include terminology such as “believe,” “will,” “may,” “estimate,” “continue,” “anticipate,” “contemplate,” “intend,” “target,” “project,” “should,” “plan,” “expect,” “predict,” “could,” “potentially” or the negative of these terms. Forward looking statements are our current statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned clinical development, the timing of and our ability to initiate or enroll clinical trials, and our ability to make regulatory filings and obtain and maintain regulatory approvals for lonafarnib, ubenimex, PEG IFN lambda, exendin 9-39 and our other product candidates, our intellectual property

position, the potential safety, efficacy, reimbursement, convenience clinical and pharmacoeconomic benefits of our product candidates, commercial opportunities, including potential market sizes and segments, our ability to commercialize, expectations regarding clinical trial data and FDA outcomes, including whether we will be able to reach agreement on a single pivotal study for lonafarnib and the nature and scope of any such study to support approval, our results of operations, cash needs, financial condition, liquidity, prospects, growth and strategies, the industry in which we operate and the trends that may affect the industry or us.

Various important factors could cause actual results or events to differ materially from the forward-looking statements that Eiger makes, including the risks described in the “Risk Factors” sections in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 and Eiger’s periodic reports filed with the SEC. Eiger does not assume any obligation to update any forward-looking statements, except as required by law.



SOURCE: Eiger BioPharmaceuticals, Inc.

Investors: Ingrid Choong, PhD

Phone: 650-619-6115

Email: ichoong@eigerbio.com